secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001650664-24-000138
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports positive RUBY trial data: 27/28 SCD patients VOE-free, HbF 48% at month 6
--------------------------------------------------------------------------------

- As of Oct 29, 2024, 28 SCD patients treated; 27 VOE-free post-reni-cel; median follow-up 9.5 months.
- Mean total hemoglobin increased from 9.8 g/dL at baseline to 13.8 g/dL at Month 6 (n=18).
- Mean HbF percentage reached 48.1% at Month 6; F-cells >90% from Month 4; MCH-F above anti-sickling threshold.
- All evaluable patients engrafted; median time to neutrophil engraftment 23 days, platelet 25 days.
- Two SAEs possibly related to reni-cel reported; safety consistent with myeloablative conditioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000138/0001650664-24-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000138/edit-20241206.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer